Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 83-91

  Yamanegi, Koji ^a   Yamane, Junko ^a   Kobayashi, Kenta ^a   Kato Kogoe, Nahoko ^a   Ohyama, Hideki ^a   Nakasho, Keiji ^a   Yamada, Naoko ^a   Hata, Masaki ^a   Fukunaga, Satoru ^a   Futani, Hiroyuki ^a   Okamura, Haruki ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Fas; Hydralazine; MHC class I related chain molecule; Osteosarcoma; Valproic acid

Indexed keywords

FAS ANTIGEN; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MHC CLASS 1 RELATED CHAIN MOLECULE A; MHC CLASS 1 RELATED CHAIN MOLECULE B; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OSTEOSARCOMA; OSTEOSARCOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG SYNERGISM; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDRALAZINE; KILLER CELLS, NATURAL; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; TUMOR ESCAPE; VALPROIC ACID;

EID: 84862840809     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1438     Document Type: Article

References (40)

1. Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943, 2008.
2. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
3. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H and Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265: 528-530, 1994. (Pubitemid 24264998)
4. Arase H, Arase N and Saito T: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181: 1235-1238, 1995.
5. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
6. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ and Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762, 1994. (Pubitemid 24131584)
7. Cascino I, Fiucci G, Papoff G and Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154: 2706-2713, 1995.
8. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG and Bartos DP: Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 94: 1-8, 1995.
9. Salih HR, Rammensee HG and Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002. (Pubitemid 35178177)
10. Salih HR, Goehlsdorf D and Steinle A: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67: 188-195, 2006. (Pubitemid 43673929)
11. Boutet P, Agüera-González S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómets M: Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182: 49-53, 2009.
12. Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738, 2002. (Pubitemid 35177960)
13. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S and Pistoia V: Down-regulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6: 558-568, 2004. (Pubitemid 39411093)
14. Märten A, Von Lilienfeld M, Büchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 119: 2359-2365, 2006. (Pubitemid 44546956)
15. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
16. Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 625: 131-142, 2009.
17. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A and Salih HR: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005. (Pubitemid 40994418)
18. Schmudde M, Braun A, Pende D, Sonnenmann J, Kiler U, Beck JF, Moretta L and Bröker BM: Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 272: 110-121, 2008.
19. Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58: 1275-1285, 2009.
20. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23: 641-648, 2009.
21. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T, Fukunaga S, Futani H, Okamura H and Terada N: Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligand, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 24: 1621-1627, 2010.
22. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S snd Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005. (Pubitemid 40215840)
23. Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G and Bernardini S: Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs 17: 1141-1150, 2006. (Pubitemid 44673394)
24. Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M, Yasumi T, Watanabe K, Nishikomori R, Nakayama T, Yonehara S, Toguchida J and Nakahata T: FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22: 9231-9242, 2003. (Pubitemid 38122035)
25. Watanabe K, Okamoto K and Yonehara S: Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12: 10-18, 2005. (Pubitemid 40090024)
26. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse AW and Galle PR: Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15: 227-230, 2006.
27. Yamanegi K, Yamane J, Hata M, Ohyama H, Yamada N, Kato-Kogoe N, Futani H, Nakasho K, Okamura H and Terada N: Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 135: 879-889, 2009.
28. Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, Kopper L, Brent TP and Houghton JA: Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10: 211-217, 2003. (Pubitemid 36553463)
29. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS, Zhang WG, Huang AL, Steinle A and Ren H: Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun 370: 578-583, 2008.
30. Johannessen CU and Johannessen SI: Valproate: past, present, and future. CNS Drug Rev 9: 199-216, 2003. (Pubitemid 36903892)
31. Spina E and Perugi G: Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 6: 57-75, 2004. (Pubitemid 38808120)
32. Kandler MR, Mah GT, Tejani AM and Stabler SN: Hydralazine for essential hypertension. Cochrane Database Syst Rev 8: CD004934, 2010.
33. Cho HJ, Lee TS, Park JB, Park KK, Choe JY, Sin DI, Park YY, Moon YS, Lee KG, Yeo JH, Han SM, Cho YS, Choi MR, Park NG, Lee YS and Chang YC: Disulfiran suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40: 1069-1076, 2007.
34. Xin ZF, Kim YK and Jung ST: Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 28: 105, 2009.
35. Venkataraman GM, Suciu D, Groh V, Boss JM and Spies T: Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 178: 961-969, 2007. (Pubitemid 46095169)
36. Lee KH, Choi EY, Kim MK, Kim KO, Jang BI, Kim SW, Kim SW, Song SK and Kim JR: Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 343: 163-171, 2010.
37. Mitmarker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH and Shen WT: Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 149: 504-511, 2011.
38. Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G and Devaki T: Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinase 2 and 9 mRNA and protein expression in lung cancer cells (A549). Chem Biol Interact 165: 220-229, 2007. (Pubitemid 46227368)
39. Song Y and Zhang C: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol 63: 605-613, 2009.
40. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G and Duenas-Gonzalez A: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6: 2, 2006.